ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
MannKind Corp. is developing a next-generation inhalation system for pulmonary delivery of drug powders based on its Technosphere technology. The company's ultra-rapid-acting insulin product, Afresa, which is under FDA review, uses this technology. Meanwhile, MannKind's $33 million deal to purchase a large quantity of insulin and Pfizer's Frankfurt, Germany, insulin factory has fallen through after Sanofi-Aventis exercised its right to acquire the plant. Sanofi's move "actually saves us a lot of money," MannKind CEO Alfred E. Mann says. "We didn't really want the factory; we just wanted all the insulin." Having enough insulin on hand to supply its current needs, the company probably won't require a plant for six to seven years, he adds.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter